Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters

Wouters, Elise; Verbrugghe, Caro; Abdelnabi, Rana; Devloo, Rosalie; Clippel, Dorien De; Jochmans, Dirk; Bleser, Dominique De; Weynand, Birgit; Compernolle, Veerle; Neyts, Johan; Feys, Hendrik B.

doi:10.1016/j.ebiom.2023.104597

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration of human CCP resulted in a reactive (immune) response in hamster lungs, whose contribution compared to viral neutralization could not be discerned. 57 …”

Section: Resultsmentioning

confidence: 99%

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy

Focosi,

Maggi

2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Convalescent plasma has been extensively tested during the COVID-19 pandemic as a transfusion product. Similarly, monoclonal antibodies have been largely administered either intravenously or intramuscularly. Nevertheless, when used against a respiratory pathogen, respiratory delivery is preferable to maximize the amount of antibody that reaches the entry door in order to prevent sustained viral multiplication. In this narrative review, we review the different types of inhalation device and summarize evidence from animal models and early clinical trials supporting the respiratory delivery (for either prophylactic or therapeutic purposes) of convalescent plasma or monoclonal antibodies (either full antibodies, single-chain variable fragments, or camelid-derived monoclonal heavy-chain only antibodies). Preliminary evidences from animal models suggest similar safety and noninferior efficacy, but efficacy evaluation from clinical trials is still limited.

show abstract